J Wesson Ashford

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi Designing a Brief Alzheimer Screen (BAS)
    Marta S Mendiondo
    School of Public Health, Sanders Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA
    J Alzheimers Dis 5:391-8. 2003
  2. ncbi MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia
    J W Ashford
    War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, CA, USA
    J Alzheimers Dis 26:331-6. 2011
  3. ncbi P300 energy loss in aging and Alzheimer's disease
    J Wesson Ashford
    War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, CA 94304 1290, USA
    J Alzheimers Dis 26:229-38. 2011
  4. ncbi APOE genotype effects on Alzheimer's disease onset and epidemiology
    J Wesson Ashford
    Stanford VA Alzheimer Center, Palo Alto, CA 94304 1207, USA
    J Mol Neurosci 23:157-65. 2004
  5. ncbi What is aging? What is its role in Alzheimer's disease? What can we do about it?
    J Wesson Ashford
    Stanford VA Alzheimer Center, Palo Alto, CA 94304 1207, USA
    J Alzheimers Dis 7:247-53; discussion 255-62. 2005
  6. ncbi Measuring memory in large group settings using a continuous recognition test
    J Wesson Ashford
    Stanford VA Aging Clinical Research Center, VA Palo Alto Health Care System, Palo Alto, CA 94304 1290, USA
    J Alzheimers Dis 27:885-95. 2011
  7. ncbi Apolipoprotein E epsilon4 influences on episodic recall and brain structures in aging pilots
    Maheen M Adamson
    Department of Veterans Affairs, Palo Alto, CA 94304, USA
    Neurobiol Aging 31:1059-63. 2010
  8. ncbi Acetylcholinesterase inhibitor in combination with cognitive training in older adults
    Jerome A Yesavage
    Palo Alto Veterans Affairs Health Care System, Palo Alto, CA, USA
    J Gerontol B Psychol Sci Soc Sci 63:P288-94. 2008
  9. ncbi Strategies to reduce site differences in multisite studies: a case study of Alzheimer disease progression
    Art Noda
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA
    Am J Geriatr Psychiatry 14:931-8. 2006
  10. ncbi Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury
    Joshua D Halbauer
    Department of Veterans Affairs VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
    J Rehabil Res Dev 46:757-96. 2009

Collaborators

Detail Information

Publications16

  1. ncbi Designing a Brief Alzheimer Screen (BAS)
    Marta S Mendiondo
    School of Public Health, Sanders Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA
    J Alzheimers Dis 5:391-8. 2003
    ..With advances in the treatment of Alzheimer's disease (AD), clinical focus has shifted to early patient identification. Memory recall tests and category fluency distinguish normal individuals from early AD patients...
  2. ncbi MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia
    J W Ashford
    War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, CA, USA
    J Alzheimers Dis 26:331-6. 2011
    ..The objective of this study was to test whether memantine would slow or prevent the loss of neurons in mild to moderate AD patients...
  3. ncbi P300 energy loss in aging and Alzheimer's disease
    J Wesson Ashford
    War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, CA 94304 1290, USA
    J Alzheimers Dis 26:229-38. 2011
    ..The approaches to calculating the P300 described here are potentially useful for measuring specific neural systems affected by aging and AD...
  4. ncbi APOE genotype effects on Alzheimer's disease onset and epidemiology
    J Wesson Ashford
    Stanford VA Alzheimer Center, Palo Alto, CA 94304 1207, USA
    J Mol Neurosci 23:157-65. 2004
    ..This paper reviews the onset, diagnosis, and epidemiology of AD, specifically with regard to the APOE genotype and the interaction of the genotype with age...
  5. ncbi What is aging? What is its role in Alzheimer's disease? What can we do about it?
    J Wesson Ashford
    Stanford VA Alzheimer Center, Palo Alto, CA 94304 1207, USA
    J Alzheimers Dis 7:247-53; discussion 255-62. 2005
  6. ncbi Measuring memory in large group settings using a continuous recognition test
    J Wesson Ashford
    Stanford VA Aging Clinical Research Center, VA Palo Alto Health Care System, Palo Alto, CA 94304 1290, USA
    J Alzheimers Dis 27:885-95. 2011
    ..There were no significant effects of gender on test performance. Such memory tests represent a practical and novel approach to screen for the signs of early dementia...
  7. ncbi Apolipoprotein E epsilon4 influences on episodic recall and brain structures in aging pilots
    Maheen M Adamson
    Department of Veterans Affairs, Palo Alto, CA 94304, USA
    Neurobiol Aging 31:1059-63. 2010
    ..These findings point to basic memory testing as a sensitive tool for detecting APOE epsilon4-related influences on memory in aging workers...
  8. ncbi Acetylcholinesterase inhibitor in combination with cognitive training in older adults
    Jerome A Yesavage
    Palo Alto Veterans Affairs Health Care System, Palo Alto, CA, USA
    J Gerontol B Psychol Sci Soc Sci 63:P288-94. 2008
    ....
  9. ncbi Strategies to reduce site differences in multisite studies: a case study of Alzheimer disease progression
    Art Noda
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA
    Am J Geriatr Psychiatry 14:931-8. 2006
    ....
  10. ncbi Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury
    Joshua D Halbauer
    Department of Veterans Affairs VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
    J Rehabil Res Dev 46:757-96. 2009
    ..With a multidimensional approach (such as the biopsychosocial model) applied to each symptom cluster, psychological, occupational, and social dysfunction can be delineated and managed...
  11. ncbi ApoE genotype accounts for the vast majority of AD risk and AD pathology
    Jacob Raber
    Departments of Behavioral Neuroscience and Neurology, L470, ONPRC, Oregon Health and Science University, 3181 S W Sam Jackson Park Road, Portland, OR 97201, USA
    Neurobiol Aging 25:641-50. 2004
    ..Thus, the epidemiologic and basic science evidence suggest that apoE genotype accounts for the vast majority of AD risk and pathology...
  12. ncbi Non-familial Alzheimer's disease is mainly due to genetic factors
    J Wesson Ashford
    Department of Psychiatry, Sanders Brown Center on Aging, University of Kentucky, Veterans Affairs Medical Center, Lexington, KY 40536 0230, USA
    J Alzheimers Dis 4:169-77. 2002
    ..This paper further reviews the mechanisms associated with AD causation for APOE and other candidate genes and implications for the development of prevention strategies...
  13. ncbi Live discussion. From here to there: AbetaPP as an axonal transport receptor--how could this explain neurodegeneration in AD. 15 July 2002
    Larry Goldstein
    University of California, San Diego, USA
    J Alzheimers Dis 5:483-9. 2003
  14. ncbi Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells
    Steven J Greco
    Neurotez Inc, Bridgewater, NJ, USA
    Biochem Biophys Res Commun 376:536-41. 2008
    ..Thus, leptin, which ameliorates both amyloid beta and tau-related pathological pathways, holds promise as a novel therapeutic for Alzheimer's disease...
  15. ncbi Neuroplasticity in Alzheimer's disease
    Bruce Teter
    Department of Medicine, University of California Los Angeles, California and Veteran's Affairs-Greater Los Angeles Healthcare System, Sepulveda, California 91343, USA
    J Neurosci Res 70:402-37. 2002
    ..These mechanisms, however, may contribute to the vulnerability to neurodegenerative disease. They may also be exploited therapeutically to help alleviate the suffering from neurodegenerative conditions...
  16. ncbi ApoE4: is it the absence of good or the presence of bad?
    J Wesson Ashford
    101 Sanders Brown Building, University of Kentucky, College of Medicine, University of Kentucky, Lexington, KY 40536 0230, USA
    J Alzheimers Dis 4:141-3. 2002